FDA-approved
Bones & muscles
Palopegteriparatide
Evidence
FDA approved
Class
Long-acting parathyroid hormone prodrug
KEY TAKEAWAY
Palopegteriparatide is teriparatide attached to a carrier that releases it slowly over a day. It is sold as Yorvipath. The FDA approved palopegteriparatide (Yorvipath) in August 2024 for adults with hypoparathyroidism.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting parathyroid hormone prodrug
Approved for
Hypoparathyroidism in adults
Key fact
The FDA approved palopegteriparatide (Yorvipath) in August 2024 for adults with hypoparathyroidism.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Palopegteriparatide is teriparatide attached to a carrier that releases it slowly over a day. It is sold as Yorvipath.
It replaces the parathyroid hormone that people with hypoparathyroidism cannot make, which raises blood calcium.
The FDA approved palopegteriparatide (Yorvipath) in August 2024 for adults with hypoparathyroidism.
Hypoparathyroidism in adults.
Injection-site reactions, high or low blood calcium and headache are reported.
U.S. FDA prescribing information for Palopegteriparatide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.